RG7834 Derivative: Preclinical Data for an Oral Hepatitis B Antigen Inhibitor

Preclinical data for a tetracyclic dihydroquinolizinone compound (6S,10S)-57, a derivative of the HBsAg production inhibitor RG7834. The dataset likely contains experimental results from structure optimization, in vitro potency (EC50 = 0.63 nM), hepatoselectivity (liver-to-blood ratio = 13.4), and in vivo efficacy in an AAV-HBV mouse model. Author Ruoyu Dong uploaded the 5.4 KB CSV file to figshare in April 2026.

Use Cases

• Modeling structure-activity relationships based on the systematic optimization from RG7834.
• Analyzing hepatoselectivity metrics based on the reported liver-to-blood distribution ratio.
• Comparing in vitro potency and neurotoxicity decoupling based on EC50 and neurite outgrowth inhibition data.
• Evaluating in vivo efficacy in animal models based on the reported log reduction of serum HBsAg.

Strengths

• Includes specific, quantitative preclinical metrics: EC50 of 0.63 nM and liver-to-blood ratio of 13.4.
• Describes a clear research progression from a clinical-stage candidate (RG7834) to an optimized derivative.
• File is small (5.4 KB) and in CSV format, suggesting straightforward access and parsing.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for statistical analysis.
• Data scope is limited to a single compound and its preclinical profile.

Provenance

Source

Ruoyu Dong via figshare.

Collection Method

Likely contains synthesized experimental results from medicinal chemistry optimization and preclinical testing.

Time Range

null

Freshness

Last updated 2026-04-24 10:43:30; freshness should be verified.

Geography

null